Iron oxide particles for atheroma imaging

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 7, 2009, Pages 1001-1008

  Tang, Tjun Y ^a   Muller, Karin H ^b   Graves, Martin J ^a   Li, Zhi Y ^a   Walsh, Stewart R ^a   Young, Victoria ^a   Sadat, Umar ^a   Howarth, Simon P S ^a   Gillard, J H ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherosclerosis; Carotid atheroma; Inflammation; MRI; Plaque vulnerability; USPIO

Indexed keywords

ATORVASTATIN; CONTRAST MEDIUM; FERUMOXTRAN 10; IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; IRON; OXIDE;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CLINICAL TRIAL; CORONARY BLOOD VESSEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG HALF LIFE; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; ANIMAL; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CHEMISTRY; METHODOLOGY; MOUSE; RABBIT; SYNTHESIS;

ANIMALS; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MICE; OXIDES; RABBITS;

EID: 67650331089     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.165514     Document Type: Review

References (50)

1. Virmani R, Ladich ER, Burke AP, Kolodgie FD. Histopathology of carotid atherosclerotic disease. Neurosurgery. 2006;59:S219-S227; discussion S213-S213.
2. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S-460S.
3. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: Current imaging methods and new perspectives. Stroke. 2005;36: 2764-2772.
4. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103: 415-422.
5. Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: Critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging. 2005;21:432-442.
6. Herborn CU, Vogt FM, Lauenstein TC, Dirsch O, Corot C, Robert P, Ruehm SG. Magnetic resonance imaging of experimental atherosclerotic plaque: Comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging. 2006;24:388-393.
7. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, Chillon S, Henin D, Jacob MP, Letourneur D, Feldman LJ. Ferumoxtran-10-enhanced mri of the hypercholesterolemic rabbit aorta: Relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol. 2006;26:176-181.
8. Trivedi RA, Mallawarachi C, U. King-Im JM, Graves MJ, Horsley J, Goddard MJ, Brown A, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. Identifying inflamed carotid plaques using in vivo uspio-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26:1601-1606.
9. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453-2458.
10. Tang T, Howarth SP, Miller SR, Trivedi R, Graves MJ, King-Im JU, Li ZY, Brown AP, Kirkpatrick PJ, Gaunt ME, Gillard JH. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 2006;37:2266-2270.
11. Trivedi RA, U-King-Im JM, Graves MJ, Kirkpatrick PJ, Gillard JH. Noninvasive imaging of carotid plaque inflammation. Neurology. 2004; 63:187-188.
12. Trivedi RA, JM UK-I, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. In vivo detection of macrophages in human carotid atheroma: Temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631-1635.
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
14. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, Bulte JW, Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med. 2003;50:411-416.
15. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials. 2003;24:1001-1011.
16. Foster-Gareau P, Heyn C, Alejski A, Rutt BK. Imaging single mammalian cells with a 1.5 t clinical MRI scanner. Magn Reson Med. 2003; 49:968-971.
17. Kawahara I, Nakamoto M, Kitagawa N, Tsutsumi K, Nagata I, Morikawa M, Hayashi T. Potential of magnetic resonance plaque imaging using superparamagnetic particles of iron oxide for the detection of carotid plaque. Neurol Med Chir (Tokyo). 2008;48:157-161; discussion 161-152.
18. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. Eur Radiol. 2007;17:3017-3024.
19. Taktak S, Sosnovik D, Cima MJ, Weissleder R, Josephson L. Multiparameter magnetic relaxation switch assays. Anal Chem. 2007;79: 8863-8869.
20. Harisinghani MG, Dixon WT, Saksena MA, Brachtel E, Blezek DJ, Dhawale PJ, Torabi M, Hahn PF. MR lymphangiography: Imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics. 2004;24:867-878.
21. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging. 1997;7:1140-1145.
22. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: Methods and techniques. Transplantation. 2003;76:1123-1130.
23. Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny EJ, Daldrup-Link HE. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol. 2004;14:1851-1858.
24. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: Mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004;39:56-63.
25. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23:1418-1423.
26. Williams JB, Ye Q, Hitchens TK, Kaufman CL, Ho C. MRI detection of macrophages labeled using micrometer-sized iron oxide particles. J Magn Reson Imaging. 2007;25:1210-1218.
27. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2008;29: 3583-3590.
28. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: The effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta. 1986;881:307-313.
29. von Zur Muhlen C, von Elverfeldt D, Bassler N, Neudorfer I, Steitz B, Petri-Fink A, Hofmann H, Bode C, Peter K. Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor mac-1 (cd11b/cd18): Implications on imaging of atherosclerotic plaques. Atherosclerosis. 2007;193:102-111.
30. Muller K, Skepper JN, Posfai M, Trivedi R, Howarth S, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials. 2007;28:1629-1642.
31. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. Mri-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med. 2003;50:309-314.
32. Leenders W. Ferumoxtran-10 advanced magnetics. IDrugs. 2003;6: 987-993.
33. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol. 1990;186:1-85.
34. Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S, Rosenbrock H, Keller U, Heinzmann U, Rummeny EJ, Schlegel J, Link TM. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology. 2003;228:760-767.
35. Schulze E, Ferrucci JT Jr, Poss K, Lapointe L, Bogdanova A, Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol. 1995;30:604-610.
36. Tang TY, Miller SR, Graves MJ, Howarth SP, Patterson AJ, U-King-Im J-M, Yong ZY, Brown AP, Kirkpatrick PJ, Boyle JR, Gaunt ME, Gillard JH Effects of aggressive versus conventional lipid-lowering therapy by atorvastatin on inflammatory activity in human carotid atherosclerotic plaques: A prospective randomised double-blind trial with uspioenhanced high resolution magnetic resonance imaging. Proceedings of the 57th annual scientific session of the American College of Cardiology. 2008:94.
37. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: Implications for targeted magnetic resonance plaque imaging. Atherosclerosis. 2005;178:67-73.
38. Muller K, Skepper JN, Tang TY, Graves MJ, Patterson AJ, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (ferumoxtran-10) in human monocyte-macrophages: Implications for magnetic resonance imaging. Biomaterials. 2008;29:2656-2662.
39. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001;14:355-361.
40. Chambon C, Clement O, Le Blanche A, Schouman-Claeys E, Frija G. Superparamagnetic iron oxides as positive MR contrast agents: In vitro and in vivo evidence. Magn Reson Imaging. 1993;11:509-519.
41. Yarnykh VL, Yuan C. T1-insensitive flow suppression using quadruple inversion-recovery. Magn Reson Med. 2002;48:899-905.
42. Howarth SP, Tang TY, Trivedi R, Weerakkody R, J UK-I, Gaunt ME, Boyle JR, Li ZY, Miller SR, Graves MJ, Gillard JH. Utility of uspio-enhanced MR imaging to identify inflammation and the fibrous cap: A comparison of symptomatic and asymptomatic individuals. Eur J Radiol. In press.
43. Naylor AR, John T, Howlett J, Gillespie I, Allan P, Ruckley CV. Fate of the non-operated carotid artery after contralateral endarterectomy. Br J Surg. 1995;82:44-48.
44. Halliday AW, Thomas DJ, Mansfield AO. The asymptomatic carotid surgery trial (acst). Int Angiol. 1995;14:18-20.
45. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Trivedi RA, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, Gaunt ME, Gillard JH. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: An ultra small superparamagnetic iron oxide enhanced magnetic resonance study. J Neurol Neurosurg Psychiatry. 2007;78:1337-1343.
46. Crowe L. Ex vivo mr imaging of atherosclerotic rabbit aorta labeled with uspio - enhancement of iron loaded regions in ute imaging. Proc Intl Soc Mag Reson Med. 2005;13:115.
47. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Li ZY, Walsh SR, Hayes PD, Varty K, Gillard JH. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques in patients with asymptomatic carotid stenosis undergoing coronary artery bypass grafting: An ultrasmall superparamagnetic iron oxide enhanced magnetic resonance study. Eur J Vasc Endovasc Surg. 2008;35:392-398.
48. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo mri of brain inflammation in human ischaemic stroke. Brain. 2004;127:1670-1677.
49. Izquierdo-Garcia D, Davies JR, Graves MJ, Rudd JH, Gillard JH, Weissberg PL, Fryer TD, Warburton EA. Comparison of methods for magnetic resonance-guided [18-f]fluorodeoxyglucose positron emission tomography in human carotid arteries: Reproducibility, partial volume correction, and correlation between methods. Stroke. 2009;40:86-93.
50. Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, Ozgun M, Nagel E, Vymazal J, Graham PB, Gunther RW, Maintz D. MR imaging of thrombi using ep-2104r, a fibrin-specific contrast agent: Initial results in patients. Eur Radiol. 2008;18:1995-2005.